树突状细胞-细胞因子诱导的杀伤细胞对恶性血液肿瘤患者免疫功能的影响

目的 观察应用树突状细胞-细胞因子诱导的杀伤细胞（DC-CIK细胞）治疗恶性血液肿瘤对患者外周血T淋巴细胞亚群和免疫蛋白的影响.方法 选择25例恶性血液肿瘤患者,采集外周血单个核细胞,经体外培养获得DC-CIK细胞,并将质检合格的DC-CIK细胞分4次回输给患者,分别于治疗前和治疗后3周抽取外周静脉血,检测T淋巴细胞亚群及免疫球蛋白变化情况,与30例非肿瘤患者进行比较分析,同时观察治疗过程中的不良反应.结果 25例患者DC-CIK细胞治疗后外周血中的CD3＋、CD3＋ CD8＋、CD3＋ CD16＋ CD56＋、CD3-CD16＋ CD56＋细胞比例较输注前明显增加（P＜0.05）,CD3＋ CD4＋T细胞比例无明显变化（P＞0.05）；外周血免疫球蛋白（IgG、IgM、IgA）浓度无明显变化（P＞0.05）.DC-CIK细胞治疗过程中有2例出现短暂性低热,均可自行缓解.恶性血液肿瘤患者在DC-CIK细胞治疗前与非肿瘤患者比较,外周血CD3＋、CD4＋、NK及NKT细胞比例明显下降（P＜0.05）,外周血中的IgG、IgM及IgA浓度无明显变化（P＞0.05）.结论 DC-CIK细胞免疫治疗能显著提高恶性血液肿瘤患者体内的肿瘤杀伤性T细胞及其效应细胞的数量,改善恶性血液肿瘤患者免疫失衡状态,增强机体抗肿瘤免疫功能,且安全有效,为恶性血液肿瘤的治疗提供了新的选择.

Effects of DC-CIK cells therapy on immune function of patients with hematological malignancies

Objective To investigate the effect of dendritic cells （dendritic cell,DC） combined with cytokine-induced killer cells （cytokine-induced kill cell,CIK） on expression of T lymphocyte subsets and immunoglobul in of periheral blood in malignant tumor patients.Methods 25 cases of malignant blood tumor patients were selected.Peripheral blood mononuclear cells from 25 patients were collected and were cultured to separat into DC-CIK cells.The DC-CIK cells were infusion to patients by four times through a peripheral vein.The peripheral venous blood of patients was collected in before treatment and 3 weeks after treatment,respectively,to detect the changes of T lymphocyte subsets and immunoglobulin,and to campare with 30 cases of non-cancer patients.The adverse reactions and safety during treatment were observed.Results Compared with that before treatment,the proportions of CD3＋,CD3＋ CD8＋,CD3＋ CD16＋ CD56＋,CD3-CD16＋ CD56＋ cells in peripheral blood after treatment were significantly increased （P 〈 0.05）,while the expression of CD3＋ CD4＋ T cells and peripheral blood immunoglobulin （IgG,IgM,IgA） were not changed （P 〉 0.05）.During treatment,2 patients had a transient fever,and relieved by itself.Compared with non-cancer patients,proportions of CD3＋,CD4＋,NK and NKT cells of patients with hematological malignancies were significantly decreased （P 〈 0.05）,while the concentrations of IgG,IgM and IgA in the peripheral blood did not change （P 〉 0.05）.Conclusion DC-CIK cell immunotherapy is safe and effective,which can significantly improve the number of tumor-killing T cells and effector cells of patient and enhance the function of anti-tumor immunity.This immunotherapy will be a new treatment method for hematologic malignancies.